5 reasons to try La Roche-Posay cosmetics in your personal care

La Roche-Posay is a French cosmetic brand - a pharmaceutical line of drugs owned by the largest cosmetic concern L'OREAL.

All cosmetic products contain thermal water, which the company considers unique in its effectiveness when applied to the skin.

Here's what they write about it on the official website of La Roche-Posay:

In the very center of one of the French villages there is a thermal spring, the water of which has a healing effect on the skin. La Roche-Posay is a small village located in the center of the French region of Vienne. The village owes its world fame to the water of the spring located there, which has a particularly beneficial effect on the skin due to its high selenium content.

Already by 1617, the healing properties of La Roche-Posay thermal water were so well known that Pierre Milon, physician to Henry IV and Louis XIII, went to the source to conduct the first studies. Napoleon, then simply General Bonaparte, returning from the Egyptian campaign at the beginning of the 19th century, ordered the construction of a hospital at the spring to treat his soldiers for skin diseases. In 1897, this place received official recognition from the French Academy of Medicine. The first thermal center opened in 1905, and in 1913 the French Academy of Medicine awarded La Roche-Posay official spa resort status.

Sounds familiar, doesn't it? The L'OREAL concern also owns the Biotherm cosmetics brand, and the healing properties of the “unique” Biotherm thermal water are also advertised there. And, of course, we encountered no less “unique” thermal waters from both the Uriage and Avene companies.

Meanwhile, our skin absolutely does not care from which thermal source the water is used to make cosmetics, water is water.

And how much mineral substances from water are absorbed into the skin is not yet known for certain to science. There is an opinion that mineral elements are not absorbed from water at all. In any case, for the health and beauty of our skin we need much more than just water.

La Roche-Posay thermal water is rich in selenium. It is a well-known antioxidant. But all its beneficial properties have been scientifically proven only when taken orally, and not when applied to the skin.

According to scientific research, selenium exhibits its antioxidant properties and is active when applied to the skin only if it is present in a cosmetic preparation in the form of the compound selenomethionine (source: Journal of Cosmetic Dermatology, July 2004, pp. 149–155).

And La Roche-Posay thermal water simply contains selenium, so it cannot be reliably stated that it is particularly beneficial for our skin.

And, of course, treating dermatological diseases only with the help of LaRoche-Posay cosmetics will not work at all - it does not contain active medicinal ingredients. All “pharmacy” cosmetics can only be used as an addition to doctor’s prescriptions.

Care for sensitive skin with prebiotic formula Toleriane Sensitive Crème

This is the first La Roche-Posay treatment for sensitive skin with a prebiotic formula.
This product has an incredibly light texture that is quickly absorbed and does not leave behind an unpleasant sticky film. The cream moisturizes the skin and also reduces signs of hypersensitivity: soothes, removes the feeling of tightness, restoring a feeling of total comfort.

Expert opinion

Alexander Prokofiev, dermatovenerologist and medical expert of the La Roche-Posay brand “The prebiotic formula regulates the skin microbiome (this is a collection of billions of bacteria living on the surface of the skin) and strengthens its natural protective barrier: the skin loses less moisture and is better protected from the effects of aggressive external factors environment: wind, polluted and (or) dry air, temperature changes.”

Financial data [edit]

Financial data in billions of Swiss francs
[69] [70] [71]

Corrective cream-gel for oily acne-prone skin Effaclar Duo+

This product copes well with imperfections, blackheads, clogged pores and post-acne.
This is one of the few remedies that reduces pronounced imperfections and prevents their re-formation. Its work becomes noticeable within 12 hours after application. In addition to its direct duties, the cream-gel removes oily shine and can be used as a base for makeup.

Expert opinion

Alexander Prokofiev, dermatovenereologist and medical expert of the La Roche-Posay brand “A comprehensive product for the care of problem skin that affects imperfections at every stage of their development and regulates the microbiome of acne-prone skin.”

First La Roche Posay cosmetics

The company presented its first line of cosmetics in 1989. Less than a year has passed since the world's largest holding company for the production of cosmetics, L'Oreal, invited La Roche Posey to join them.

The products of this brand are very diverse . Highly effective products of different lines are presented on the market:

• Facial skin care.
• Body care cosmetics.
• Line of cosmetics for children.
• Hair care products.
• Line of decorative cosmetics.
• A line aimed at combating skin aging.

All products of this brand undergo thorough clinical studies involving people with sensitive skin, which is why they have earned the trust of cosmetologists and dermatologists around the world. The effectiveness of La Roche Posay cosmetics lies in the consistency of its components, which help maintain the physiological balance of the skin.

Micellar water for sensitive and allergy-prone skin Ultra

Removes makeup from the face and skin around the eyes without using water and at the same time moisturizes and reduces redness.
In this “water” you will not find fragrances, dyes, alcohol or oils. Even those who wear contact lenses can use this micellar water - there will definitely be no red-eye effect. But the make-up and any contaminants from the surface of the skin will be captured and neutralized by “special agents”.

Expert opinion

Alexander Prokofiev, dermatovenerologist and medical expert of the La Roche-Posay brand “The architecture of the micellar water formula, developed by the La Roche-Posay dermatological laboratory, allowed us to combine the power of micelles and glycerin to achieve optimal effectiveness and tolerability.”

Hydreane

The purpose of this range is not only to moisturize, but also to reduce skin sensitivity. Its popularity among consumers is due to the presence of hydrolipids and many mineral substances necessary for the epidermis.

So, the line includes the following products:

• Hydreane Legere is a cream with pigments of natural origin that can even out the tone. The non-greasy and very delicate texture caused a real stir among dermatologists. It is not surprising that it was noted as one of the best cosmetics.
• Extra Riche is an extra-moisturizing emulsion rich in magnesium, selenium and hydrolipids. Experts recommend using a moisture-forming cream-lezher every day and after just 4 weeks, skin sensitivity will noticeably decrease and the condition will improve by 80%.
• The latest representative of the line is BB-Cream, which is presented in two shades: natural beige and light.

All 4 products in the Hydreane range are tested and have a quality certificate. In addition, laboratory studies and testing have proven that the products have shown their effectiveness even when other similar drugs could not cope with the problem.

Second era of growth and expansion: 1920-1945

Fritz Hoffmann-La Roche died in 1920. Burrell assumed the role of president and ushered in a new era of growth and expansion. At the same time, American Elmer H. Bobst became general manager of the company's US subsidiary. The US branch was founded in 1905, and Bobst's reign was a resounding success: under his leadership, the company introduced Allonal, a pain reliever that became the company's first million-dollar product.

Then a tragedy occurred in the Hoffmann-La Roche family, which changed the course of the company's management: Emanuel, Fritz's eldest son, died in a car accident. In the late 1930s, Emanuel's widow married Paul Sacher, founder and conductor of the Basel Chamber Orchestra. Sacher assumed control of 49 percent of the company's shares—the interests of his wife, his stepson Lukas Hoffmann and his stepson Jacob Ory, a surgeon from Basel. All three took seats on the board of directors. Sacher remained active in company decisions until the late 1980s.

In the years leading up to World War II, the company's strategy changed; he gradually moved from extracting drugs from natural sources to synthesizing them, and his most important breakthrough was the large-scale production of synthetic vitamins in large quantities. As early as 1933, Barell developed a method for synthesizing vitamin C. Later advances included vitamins A and E.

In 1971, the company had between 50 and 70 percent of the global vitamin market, and production continued to grow.

As World War II approached, the company's American subsidiary assumed greater importance. In 1928, the company's U.S. headquarters was located in Nutley, New Jersey; when the threat of war and a possible Nazi invasion of Switzerland arose, the company prepared to expand Nutley's territory. The company's interests were also transferred to the Canadian holding company Sapac. The American operations at Nutley came under the control of Sapac, whose extensive manufacturing and research operations soon made it a virtually independent company.

Company headquarters in Basel, Switzerland

Not only were the assets transferred in the early 1940s, but Emil Barell himself moved to Nutley before the end of the war. Differences in their personalities and approaches to business caused Bobst and Burrell to constantly disagree, and Bobst resigned in 1944. He then took over the struggling Warner-Lambert Company and presided over one of the pharmaceutical industry's most dramatic comebacks. Burrell hired Lawrence Barney from the prestigious Wisconsin Alumni Research Foundation to serve as president of the Americas chapter. Barney remained with Roche for the next 20 years. Emil Barell died in 1953 at the age of 79. His successor, Albert Caflisch, served until 1965.

Links[edit]

1. "Executive committee" . Roche.com
   . F. Hoffmann-La Roche. Archived from the original on September 14, 2016. Retrieved November 26 +2016.
2. "Roche Appoints New Head of $13 Billion Diagnostics Unit". Reuters
   . June 11, 2022.
3. "FDA grants breakthrough therapy to Roche for hemophilia drug". BioPharm International
   . UBM. April 19, 2022. Retrieved April 20, 2022.
4. ^ abcdef "Financial Report 2020" (PDF). Roche Holding. February 4, 2022. Retrieved February 5, 2022.
5. “Who are the top 10 pharmaceutical companies in the world? (2020) | Pro-clinical blogs". Proclinical
   .
6. “Top 10 Oncology Pharmaceutical Companies in the World | Marketing Research Blog". Market Research Reports®
   Inc. May 17, 2022.
7. "Top 20 Pharmaceutical Companies by Oncology Sales - List of Top Pharmaceutical Companies - PMLiVE". www.pmlive.com
   . June 16, 2014
8. ^ ab "Financial Report 2018" (PDF). Roche Holding. Retrieved February 1, 2022.
9. "The Pharmaceutical Industry in Figures - 2008 Edition" . European Federation of Pharmaceutical Industries and Associations (EFPIA). item 49. Archived from the original on September 16, 2008. Retrieved August 25, 2008.
10. Roche Biomedical Laboratories, Inc. . FundingUniverse.com.
11. "HIV Surveillance—United States, 1981–2008". Retrieved November 8, 2013.
12. Laboratory Corp of America Holdings · 10-Q · Dated 03/31/95, SECInfo.com, filed 05/15/95, SEC File 1-11353, Registration No.
13. "Roche, Gilead End Tamiflu Feud". Red herring
    . November 16, 2005
14. Kher, Unmesh (19 October 2005). "Why Roche released Tamiflu". Time
    . Time Inc. Retrieved May 22, 2008.
15. "Roche - Roche acquires Swiss company GlycArt Biotechnology to strengthen its expertise in antibody therapeutic research". roche.com. Archived from the original on February 5, 2015. Retrieved April 29, 2015.
16. Representation: GlycArt Biotechnology AG Since the creation of the trade sale – and what happened after... Dr. Joël Jean-Mairet. Brussels, March 31, 2011
17. Cameron, F; McCormack, Poland (January 2014). "Obinutuzumab: First global approval." Drugs
    .
    74
    (1): 147–54. DOI: 10.1007/s40265-013-0167-3. PMID 24338113. S2CID 40983655.
18. "Roche buys Ventana". Archived from the original on June 5, 2014. Retrieved June 2, 2014.
19. ↑
    Pollack, Andrew (March 12, 2009).
    "Roche buys Memory Pharmaceuticals". New York Times
    . Retrieved June 2, 2014.
20. ↑
    Pollack, Andrew (March 12, 2009).
    "Roche buys Genentech". New York Times
    . Retrieved June 2, 2014.
21. ↑
    Pollack, Andrew (February 5, 1990).
    "Genentech-Roche deal could spur similar relationships". New York Times
    . Retrieved April 11, 2009.
22. Bawden, Tom (13 March 2009). "Roche Acquires Genentech in Third Major Drug Deal". The Times
    . London. Archived from the original on June 12, 2011. Retrieved April 11, 2009.
23. Jucca, Lisa; Cage, Sam (26 March 2009). "Roche completes acquisition of Genentech". Reuters
    . Retrieved April 11, 2009.
24. "Roche buys Medingo". Archived from the original on January 12, 2014. Retrieved June 2, 2014.
25. "Roche buys BioImagene". Archived from the original on June 5, 2014. Retrieved June 2, 2014.
26. "2011 Facility of the Year Category Winners". Retrieved June 28, 2012.
27. "Roche buys PVT". Archived from the original on June 5, 2014. Retrieved June 2, 2014.
28. "Roche buys mtm labs". Archived from the original on June 5, 2014. Retrieved June 2, 2014.
29. "Roche buys Anadys". Archived from the original on June 5, 2014. Retrieved June 2, 2014.
30. "Roche acquires Verum Diagnostica GmbH for €11 million". BioSpace
    .
31. "Roche Announces Closure of Nutley, New Jersey Site". Archived from the original on May 18, 2013. Retrieved June 28, 2012.
32. "Roche buys Constitution Medical". Archived from the original on June 2, 2014. Retrieved June 2, 2014.
33. "Genentech buys Arrayit Corp. technology". BioSpace
    .
34. "Roche Buys IQuum". Archived from the original on June 2, 2014. Retrieved June 2, 2014.
35. ↑
    Copley, Caroline (7 April 2014).
    "Roche buys rights to experimental drugs from Orison". Reuters
    . Retrieved June 2, 2014.
36. Mulier, Thomas (2 June 2014). "Roche buys Zhenya". Bloomberg
    . Retrieved June 2, 2014.
37. ↑
    Michelle Cortez (August 24, 2014).
    "Roche Holdings Agrees to Buy InterMune for $8.3 Billion". Bloomberg.com
    .
38. "Roche pays 37% premium on InterMune shares in US$8.3 billion deal". San Francisco News.Net. August 24, 2014. Retrieved August 24, 2014.
39. ↑
    "Roche reaches $450 million deal with Santaris Pharma A/S".
    BioSpace
    .
40. "Roche Acquires Big Data Platform Provider". GEN
    . December 19, 2014
41. ^ ab "Roche to pay up to $489 million for next-generation solid antibodies". BioSpace
    .
42. "Roche to buy Trophos for $543 million". GEN
    . January 16, 2015.
43. "Roche Captures CAPP Medical, 'Liquid Biopsy' Launch Targeted at Cancer". BioSpace
    .
44. "Roche Acquires GeneWEAVE for Up to $425 Million". GEN
    . August 13, 2015.
45. "Roche acquires genomic tools provider Kapa Biosystems". GEN
    . August 19, 2015.
46. "Roche to acquire Adheron Therapeutics for $105 up front - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". GEN
    . October 9, 2015. Retrieved May 23, 2022.
47. "Roche Acquires Tensha Therapeutics for $115M Upfront - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". GEN
    . January 11, 2016. Retrieved May 23, 2022.
48. Inc., ForSight VISION 4. “ForSight VISION4, Inc. Announces Acquisition by Roche". prnewswire.com
    .
49. ↑
    Miller, John (30 June 2022).
    "Roche buys diabetes app firm to push digital health". Reuters
    .
50. "Roche takes cues from Bay Area amid diagnostic data push". BioSpace
    .
51. "Roche to buy US cancer drug maker Ignyta for $1.7 billion". Reuters
    . December 22, 2022 - via uk.reuters.com.
52. "Subscribe to read". Financial Times
    . Cite uses a generic header (help)
53. "Roche to buy Flatiron Health for $1.9 billion to expand cancer treatment..." Reuters
    . 15 February 2022 - via uk.reuters.com.
54. "Roche pays $2.4 billion holiday for Foundation Medicine cancer expert". Reuters
    . June 19, 2022 - via uk.reuters.com.
55. "Roche acquires cancer immunotherapy developer Tusk Therapeutics". September 28, 2022.
56. "Roche buys US biotech Jecure in race for liver disease drugs". Reuters
    . November 27, 2022 - at uk.reuters.com.
57. ↑
    Roche makes $4.3 billion bet on gene therapy."
    Reuters
    . 25 February 2022 - via uk.reuters.com.
58. "Roche says $4.3 billion Spark offering still on track to close in June". cnbc.com
    . April 3, 2022.
59. Koltrowitz, Silke; Nadim, Denmark (December 23, 2022). "Roche deepens into gene therapy with $1.15 billion licensing deal for Sarepta". Reuters
    . Retrieved December 24, 2022.
60. "Roche to acquire fibrosis-focused Promedior for up to $1.4 billion".
61. "Promedior enters into definitive merger agreement to be acquired by Roche".
62. Jump up
    ↑ Hale C. (March 2022).
    “FDA greenlights coronavirus test within 24 hours” FierceBiotech
    . Retrieved March 13, 2022.
63. "Roche buys US gene sequencing company Stratos Genomics". Reuters
    . May 22, 2022.
64. "Roche acquires Stratos Genomics to further develop DNA-based sequencing for diagnostic use".
65. "Roche dives into NLRP3 inhibition of Inflammasome with acquisition of Inflazome". BioSpace
    .
66. "Inflazome Announces Acquisition by Roche". BioSpace
    .
67. https://www.biospace.com/article/roche-acquires-genmark-diagnostics-and-its-covid-19-test-in-1-8-billion-deal/?s=79
68. https://www.reuters.com/article/us-roche-genmark/roche-buys-genmark-for-1-8-million-to-challenge-test-rivals-idUSKBN2B70JH
69. «Roche Holding Bilanz, Gewinn und Umsatz | Roche Holding Geschäftsbericht | 855167" . wallstreet-online.de
    . Retrieved November 5, 2022.
70. MarketScreener. "ROCHE HOLDING AG: Financial data, forecasts, estimates and expectations | ROG | CH0012032048 | MarketScreener". www.marketscreener.com
    . Retrieved June 3, 2022.
71. GmbH, finanzen net. «Roche Financials | Markets Insider". market.businessinsider.com
    . Retrieved June 3, 2022.
72. ↑
    Miller, John (December 19, 2022).
    "Roche touts Swiss-led R&D unit after years in Genentech's shadow". Reuters
    . Retrieved December 19, 2022.
73. "Roche stops selling acne drug Accutane". Reuters
    . June 26, 2009. Retrieved February 23 +2016.
74. ^ ab Mathiason, Nick (25 November 2001). "Final whistle". Observer
    . Retrieved September 30, 2014.
75. Corporate Crime Reporter. Corporate crime reporter. Retrieved November 24, 2013.
76. "Cartel Price Announcement: The Vitamin Industry" (PDF). International Journal of Industrial Organization
    .
    26
    . 2008
77. Mattes, William B. (2008). "Community Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (ed.). Basic concepts of toxicogenomics
    .
    Methods of Molecular Biology. 460
    . pp. 221–238. DOI: 10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
78. "InnoMed PredTox Member Organizations". Archived from the original on September 26, 2008. Retrieved August 25, 2008.
79. Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf
    . European Commission. Archived from the original on October 15, 2009. Retrieved August 25, 2008.